Evidence map›Paper›PMID 41120903›Full record

ArticleBMC cancer2025

Different detection rates of brain metastasis in different pathological types of lung cancer by

Haoqian Li, Pei Li, Shouhui Zhu, Wenhong Hou, Wei Zhao, Qingxi Yu, Jingjie Qin, Xudong Hu, Yuchun Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Spatiotemporal voxel-wise concordance betweenEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haoqian Li *Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Pei Li *Department of Respiratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shouhui ZhuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Wenhong HouDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Wei ZhaoDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Qingxi YuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jingjie QinDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xudong HuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yuchun WeiDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China. yuchunwei0000@foxmail.com.

Funding

The China Postdoctoral Science Foundation 2023M731484The National Natural Science Foundation of China 82203218The Natural Science Foundation of Shandong Province ZR2021QH008, ZR2024YQ073
6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate the utility of fluorine-18-fibroblast activation protein inhibitor (

methodsFrom December 2020 to October 2021, patients with pathologically confirmed lung cancer and suspected BM were prospectively enrolled and underwent paired

resultsA total of 76 BM lesions from 18 patients (11 males and 7 females) were evaluated. Among these, 23 lesions were detected by

conclusionsThis study revealed differences in the detection rates of BM in lung cancer types by

trial registrationInstitutional review board approval NO. SDZLEC2021-112-02.

Indexed as

Brain NeoplasmsLung NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleFluorine RadioisotopesHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesRadiopharmaceuticalsFluorine-18Fluorine RadioisotopesRadiopharmaceuticalsBrain metastasisFibroblast activation protein inhibitorLung cancerPET/CT

Identifiers

PMID41120903
PMCPMC12539065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.